

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 30<sup>th</sup> January, 2023

BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

**Sub: Outcome of the Board Meeting held on Monday, 30<sup>th</sup> January, 2023 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sardaproteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.**

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Monday, 30<sup>th</sup> January, 2023 at the Corporate Office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) which commenced at 12:00 P.M. and concluded at 02:00 P.M. *inter-alia*, transacted the following business:

1. Approved the Un-audited Financial Results of the company for the quarter and nine months ended on 31<sup>st</sup> December, 2022 and took on record the Limited Review Report thereon. (Enclosed as Annexure-A)

Further, the extract of the Un-audited Financial Results would also be published in the newspapers in compliance with Regulation 47 of Listing Regulations;

2. Took note of the Resignation of Mr. Himanshu Gupta from the post of Chief Financial Officer (CFO) of the company with effect from closure of business hours on 30<sup>th</sup> January, 2023; and
3. Approved the appointment of Mr. Somya Data as the Chief Financial Officer (CFO) of the company with effect from 01<sup>st</sup> February, 2023.

Further, the brief profile and other details in accordance with SEBI circular CIR/CFD/CMD/4/2015 dated 09.09.2015 to be provided separately.

#### TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from Thursday, 02<sup>nd</sup> February, 2023 for all Designated Persons and their relatives.

You are requested to kindly take the same on record.

Thanking you,  
Yours faithfully,

**FOR SARDA PROTEINS LTD**

For SARDA PROTEINS LTD

  
Company Secretary

**AMIT KUMAR MODI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**  
**M.NO.: A29371**

Encl: a/a

**Reg. Office:** B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

**Corp. office:** Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

**Contact No.:** +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

# SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)  
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com  
CIN: L15142RJ1991PLC006353

## STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2022

Rs.in Lakhs

S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from Operations	226.50	279.21	274.00	505.71	418.34	1,075.98
II.	Other Income	4.28	2.48	2.93	11.93	7.57	8.54
III.	<b>Total Income (I+II)</b>	<b>230.78</b>	<b>281.69</b>	<b>276.93</b>	<b>517.64</b>	<b>425.91</b>	<b>1,084.52</b>
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	224.84	275.57	267.01	500.41	410.34	1,028.63
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	3.62	3.31	3.48	10.37	10.03	12.57
	Finance Cost	-	-	-	-	0.02	0.02
	Depreciation and Amortisation Expenses	-	-	0.02	-	0.06	0.05
	Other expenses	2.15	2.54	0.82	6.20	3.84	7.73
	<b>Total Expenses (IV)</b>	<b>230.61</b>	<b>281.42</b>	<b>271.33</b>	<b>516.98</b>	<b>424.29</b>	<b>1,049.00</b>
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	0.17	0.27	5.60	0.66	1.62	35.52
VI.	Exceptional Items	-	-	-	-	-	0.24
VII.	Profit/(Loss) before Tax (V-VI)	0.17	0.27	5.60	0.66	1.62	35.28
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	4.53
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	0.17	0.27	5.60	0.66	1.62	30.75
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	0.17	0.27	5.60	0.66	1.62	30.75
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	0.17	0.27	5.60	0.66	1.62	30.75
XVI.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVII.	Earnings per Equity Share						
	(1) Basic	0.01	0.02	0.32	0.04	0.09	1.78
	(2) Diluted	0.01	0.02	0.32	0.04	0.09	1.78

**Notes:**


1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 30th January 2023.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products".
4. No Investor Complaints were received during the quarter ended 31-Dec-2022 nor any pending as on 01-Jan-2023.



Place: Jaipur  
Date: 30-Jan-2023

on behalf of the Board  
Sarda Proteins Ltd

Deepak Data (DIN: 01672415)  
Managing Director



UDIN: 23072854 BGVZ V X 4520



*Khetawat Agarwal & Co.*  
*Chartered Accountants*

**Limited Review Report**  
**Unaudited Standalone Quarterly Results**

To  
The Board of Directors  
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter ended on 31<sup>st</sup> December, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Khetawat Agarwal & Co.**  
**Chartered Accountants**  
**FRN: 003960C**



**M.L. Agarwal**  
**Partner**  
**M. No.: 072854**



**UDIN : 23072854BGVZVX4528**

**Place : Jaipur**  
**Date : 30.01.2023**

---

**Office : 103, 1<sup>st</sup> Floor, City Center, Ashok Circle, Alwar-301001 (Rajasthan)**  
**Phone : Office 0144 - 2340924, 7014347644**  
**Mobile : 9414215353 (ML Agarwal)**  
**E-mail : khetawatagarwal21@gmail.com**